B-hCLDN18.2 A549_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Common name	B-hCLDN18.2 A549	Catalog number	310791
Aliases	OASFTA5, SFTPJ	Disease	Carcinoma
Organism	Human	Strain	--
Tissue types	Lung	Tissue	Lung

Description

The human CLDN18.2 coding sequence was inserted into the AAVS1 locus in A549 cells. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 A549 cells.

Application

B-hCLDN18.2 A549 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hCLDN18.2 A549 cells. The exogenous promoter and human CLDN18.2 coding sequence was inserted into the AAVS1 locus wild-type A549.

Protein expression analysis

from clipboard

CLDN18.2 expression analysis in B-hCLDN18.2 A549 cells by flow cytometry. Single cell suspensions from wild-type A549 and B-hCLDN18.2 A549 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 A549 cells but not wild-type A549 cells. The 1-A04 clone of B-hCLDN18.2 A549 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous heterograft tumor growth of B-hCLDN18.2 A549 cells. B-hCLDN18.2 A549 cells (1x10⁷) and wild-type A549 cells (1x10⁷) were subcutaneously implanted into B-NDG mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCLDN18.2 A549 cells were able to establish tumors in vivo and can be used for efficacy studies.